#ACR19 @rheumnow Abstr #0301 @PanlarLeague Ultrasound Study Group Recommendations for Imaging in #Gout “...1st evidence-based & expert opinion recs for use of imaging in pts w gout, providing some guidelines for their use in daily clinical practice” 8 recs for imaging in gout: https://t.co/WLSrzxLKUH

One thing that really impressed me from RITAZAREM (ritux vs azathioprine maintenance following ritux induction in AAV) apart from fewer relapses with ritux, is how well it was tolerated. Not even a hypogammaglob signal! #ACR19 ABST0806 @RheumNow https://t.co/9l1jqlX0jg

RITAZAREM Trial Fixed interval 4 monthly repeat dose Rituximab vs Aza for maintenance Pop: AAV at relapse, given 375mg/m2 Rituximab seemed superior #ACR19 @rheumnow More details Abst0806

EMA has approved the subcutaneous version of CT-P13 an infliximab biosimilar based on this trial by Rene Westhovens. Equal efficacy of IV and SC CT-P13 with great maintenance on SC form. Interestingly high trough levels with SC CT-P13. #ACR19 @RheumNow Abst 807 https://t.co/hfrtJRMPdt

In you #SLE pts how do you routinely assess CV risk

Great data on reducing low benefit care in rheum pathology ordering. Reducing dsDNA requests in patients with a negative ANA #ACR19 @RheumNow Abstract 0265 https://t.co/b5gWwPi487

RheumNow’s expanded coverage of the #ACR2019 annual meeting is sponsored in part by Sanofi Genzyme and Regeneron. All content chosen by RheumNow and its faculty.

Abstract 0348 #gout Details of the changes over time in gout medications in US RISE database. Allopurinol and pegloticase slowly grinding higher… Lesinurad increased significantly in comparison @RheumNow #ACR19 https://t.co/VcqNtB2eXN

CVS risk in black patients with SLE (retro cohort) 18x higher in early SLE & over long-term, 6x Highest risk at 1 and 10yrs after SLE diagnosis Discoid rash 3x assoc with CVD #ACR19 @rheumnow Abst0805

Holy smokes! 18x higher risk of cardiovascular disease in Black SLE patients, highest at 1 and 10 years after diagnosis - Dr Shivani Garg    #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/kXoMNu4QKb

Pneumococcal vaccine recommendations for pts with AID are confusing and data is C level - but we still recommend prime/boost administration of PCV13 followed by PPSV23 @RheumNow @LCalabreseDO @BetsyKirch #ACR19 #cleclinicrheum https://t.co/WFBjQRRgmb

Plenary session shows AA/blacks at higher risk for #SLE & that blacks have 16 fold increased risk for IHD, CVD. CV risk accelerated at yrs 1 & 10. Copy & paste. #ACR19 @RheumNow Abst 805 #ACRBest https://t.co/kgfwjd1XOc

RheumNow’s expanded coverage of the #ACR2019 annual meeting is sponsored in part by Horizon Therapeutics. All content chosen by RheumNow and its faculty.

What percentage of your SLE and RA patients receive HCQ above the 5mg/kg recommended by AAO? #ACR19 @rheumnow #Abstr #ACRBest

How do you taper steroids in RA? I take a personalised approach i.e. I guess based on experience of similar pt situations & what I think the pt will tolerate. Is it evidence-based? Not really. Is there any evidence to guide it? Well...😐 @umichmedicine #ACR19 ABST0554 @RheumNow https://t.co/YFlvyYuBee